About CEL-SCI


History

CEL-SCI's story is one of vision, persistence, and survival in the face of overwhelming odds. Despite downturns in the biotech sector, lack of funding, and a lengthy clinical trial process associated with the development of its investigational therapy for advanced primary head and neck cancer, CEL-SCI is finally at the end game! Our lead investigational immunotherapy, Multikine (Leukocyte Interleukin, Injection)*, has completed Phase I and II clinical trials, and it is now in a global Phase III trial. More...


Mission and Values

Our mission is to improve the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system.

We strive to create real value for our stakeholders by developing innovative therapies that have the potential to address unmet medical needs. More...


Business Strategy

CEL-SCI's vision is to change the way cancer is treated.  We strive to develop novel immune-based therapies with potential to utilize the body's own immune defense system to fight disease while also having the potential to minimize toxicity to normal cells and organ systems. More...


Corporate Overview

CEL-SCI Corporation (NYSE MKT: CVM), a biotechnology company, was formed in 1983.

CEL-SCI is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases.

The Company's core capabilities include: drug discovery, research, development and manufacturing of complex biological substances. More...


Corporate Headquarters

CEL-SCI Corporation
8229 Boone Boulevard, Suite 802
Vienna, VA 22182  USA
Telephone (703)  506-9460
Facsimile (703) 506-9471 More...


Management Team

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.